Literature DB >> 15264223

Effects of apolipoprotein E on the human immunodeficiency virus protein Tat in neuronal cultures and synaptosomes.

Chava B Pocernich1, Rukhsana Sultana, Eugene Hone, Jadwiga Turchan, Ralph N Martins, Vittorio Calabrese, Avindra Nath, D Allan Butterfield.   

Abstract

Human immunodeficiency virus type 1 (HIV-1)-associated dementia is observed in 20-30% of patients with acquired immunodeficiency syndrome (AIDS). The epsilon4 allele of the apolipoprotein E (APOE) gene currently is thought to play a role as a risk factor for the development of HIV dementia. The HIV protein Tat is neurotoxic and binds to the same receptor as apoE, the low-density lipoprotein receptor-related protein (LRP). In this study, we investigated the role apoE plays in Tat toxicity. Synaptosomes from wild-type mice treated with Tat had increased reactive oxygen species (ROS), increased lipid and protein oxidation, and decreased mitochondrial membrane potential. Synaptosomes from APOE-knockout mice also had increased ROS, increased protein oxidation, and decreased mitochondrial membrane potential, but to a significantly lesser degree. Treatment of synaptosomes with heparinase and Tat increased Tat-induced oxidative stress, consistent with the notion of Tat requiring interaction with neuronal membranes to induce oxidative damage. Human lipidated apoE3 greatly protected neurons from Tat-induced toxicity, whereas human lipidated apoE4 showed no protection. We demonstrated that human apoE3 has antioxidant properties against Tat-induced toxicity. Taken together, the data suggest that murine apoE and human apoE4 act similarly and do not protect the cell from Tat-induced toxicity. This would allow excess Tat to remain outside the cell and interact with synaptosomal membranes, leading to oxidative stress and neurotoxicity, which could contribute to dementia associated with HIV. We show that the antioxidant properties of apoE3 greatly outweigh the competition for clearance in deterring Tat-induced oxidative stress. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15264223     DOI: 10.1002/jnr.20182

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  16 in total

1.  Genetic testing and HIV dementia: teasing out the molecular mechanisms of disease.

Authors:  Jay Rappaport; Joseph R Berger
Journal:  AIDS       Date:  2010-06-19       Impact factor: 4.177

Review 2.  Host and viral factors influencing the pathogenesis of HIV-associated neurocognitive disorders.

Authors:  Suman Jayadev; Gwenn A Garden
Journal:  J Neuroimmune Pharmacol       Date:  2009-04-17       Impact factor: 4.147

3.  Childhood trauma interacts with ApoE to influence neurocognitive function in women living with HIV.

Authors:  Jacqueline S Womersley; Georgina Spies; Soraya Seedat; Sian M J Hemmings
Journal:  J Neurovirol       Date:  2018-11-26       Impact factor: 2.643

4.  Oxidative stress and toxicity induced by the nucleoside reverse transcriptase inhibitor (NRTI)--2',3'-dideoxycytidine (ddC): relevance to HIV-dementia.

Authors:  Wycliffe O Opii; Rukhsana Sultana; Hafiz Mohmmad Abdul; Mubeen Ahmad Ansari; Avindra Nath; D Allan Butterfield
Journal:  Exp Neurol       Date:  2006-10-25       Impact factor: 5.330

5.  Relationship between apolipoprotein E4 genotype and white matter integrity in HIV-positive young adults in South Africa.

Authors:  Jacqueline Hoare; Jenny Westgarth-Taylor; Jean-Paul Fouche; Marc Combrinck; Bruce Spottiswoode; Dan J Stein; John A Joska
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-07-24       Impact factor: 5.270

Review 6.  Drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia.

Authors:  Vishnudutt Purohit; Rao Rapaka; David Shurtleff
Journal:  Mol Neurobiol       Date:  2011-07-01       Impact factor: 5.590

7.  CSF proteomic fingerprints for HIV-associated cognitive impairment.

Authors:  Juliana Pérez Laspiur; Eric R Anderson; Pawel Ciborowski; Valerie Wojna; Wojciech Rozek; Fenghai Duan; Raul Mayo; Elaine Rodríguez; Marinés Plaud-Valentín; José Rodríguez-Orengo; Howard E Gendelman; Loyda M Meléndez
Journal:  J Neuroimmunol       Date:  2007-10-22       Impact factor: 3.478

8.  Identification of putative biomarkers for HIV-associated neurocognitive impairment in the CSF of HIV-infected patients under cART therapy determined by mass spectrometry.

Authors:  Adriana Bora; Ceereena Ubaida Mohien; Raghothama Chaerkady; Linda Chang; Richard Moxley; Ned Sacktor; Norman Haughey; Justin C McArthur; Robert Cotter; Avindra Nath; David R Graham
Journal:  J Neurovirol       Date:  2014-07-24       Impact factor: 2.643

9.  Decreased glial and synaptic glutamate uptake in the striatum of HIV-1 gp120 transgenic mice.

Authors:  Roberto I Melendez; Cristina Roman; Coral M Capo-Velez; Jose A Lasalde-Dominicci
Journal:  J Neurovirol       Date:  2015-11-13       Impact factor: 2.643

Review 10.  Apolipoprotein E genotype and hepatitis C, HIV and herpes simplex disease risk: a literature review.

Authors:  Inga Kuhlmann; Anne Marie Minihane; Patricia Huebbe; Almut Nebel; Gerald Rimbach
Journal:  Lipids Health Dis       Date:  2010-01-28       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.